Healthcare advertising has long relied on claims data to identify physicians who have prescribed particular therapies, but that approach can leave media teams targeting doctors weeks after the underlying clinical decision. Doceree is attempting to shorten that gap with its new Intent Powered HCP Suite, extending real-time clinical-intent signals into CTV, social and programmatic advertising through a unified orchestration layer.
Doceree has launched its Intent Powered HCP Suite, adding connected TV, social and programmatic advertising to its healthcare marketing platform and allowing pharmaceutical brands to activate media using what the company calls real-time Clinical Intent Signals.
The announcement was made at Fierce Pharma Week 2026 and expands Doceree’s Daily Command operating system for pharma commercialization.
The central AdTech proposition is a shift from targeting physicians based primarily on what they did in the past to identifying signals that indicate what they may be considering now.
Claims data remains valuable because it provides a broad view of prescribing activity. But claims-derived audiences are inherently delayed by the processes required to adjudicate, aggregate and model prescription information. For advertisers trying to influence decisions around a therapy, that delay can create a disconnect between the clinical moment and the advertising opportunity.
Doceree’s Clinical Intent Signals are designed to address that gap. The company says its signals can include activity within electronic health record workflows, engagement with clinical content across its network of more than 2,000 medical publishers and point-of-care interactions captured through its Triggers technology.
The signals are then resolved to verified National Provider Identifiers through ESPYIAN, Doceree’s healthcare identity graph. Doceree says the graph covers more than six million healthcare professionals and uses deterministic identity resolution rather than probabilistic lookalike audiences.
That identity layer is important because healthcare advertising requires considerably more precision than simply identifying an audience by demographic or broad professional characteristics.
The new suite applies those signals across three major advertising environments.
CTV allows pharmaceutical advertisers to reach verified healthcare professionals on connected television, with creative sequencing based on active clinical intent rather than static specialty or audience lists.
Social advertising extends the model to LinkedIn, where Doceree says HCP-verified placements can be adjusted based on changing intent and frequency requirements.
Programmatic advertising takes the signals into the bidding process, allowing media spend to respond to clinical-intent indicators across Doceree’s endemic publisher network and open-exchange inventory.
The common infrastructure is Daily Command. Rather than operating separate strategies for point-of-care, CTV, social and programmatic media, advertisers can use the same clinical signal to coordinate activity across channels.
That creates a more interesting proposition than conventional audience targeting. A physician’s interaction with clinical content could potentially influence subsequent media exposure across multiple environments, allowing advertisers to sequence messaging around the same underlying event.
Doceree is also connecting the system to its existing Care Sequence platform, email and text capabilities, RepTwin and digital out-of-home offering. The company’s broader objective is to turn clinical signals into triggers for coordinated media activity rather than isolated audience segments.
For AdTech, the development reflects a wider movement toward real-time decisioning. Programmatic advertising has long used signals to determine which impressions are worth bidding on, but healthcare introduces additional complexity around identity, privacy, clinical context and regulatory requirements.
The company’s closed-loop attribution framework is therefore another important component. Doceree says advertisers can measure signal-to-exposure latency alongside conventional reach and conversion metrics.
The competitive question will be whether real-time intent signals produce materially better outcomes than established healthcare audience models while maintaining sufficient transparency and privacy controls. Pharmaceutical marketers also need confidence that identity resolution, data provenance and activation workflows meet the requirements of regulated advertising.
The larger significance is that healthcare media is moving closer to the same real-time decisioning model already common in other areas of digital advertising. Instead of building an audience once and activating it repeatedly, advertisers can potentially respond as relevant signals emerge.
If that model scales, the competitive advantage may shift from simply owning large healthcare datasets to determining which signals are predictive, how quickly they can be activated and how reliably their impact can be measured.
Market Landscape
Healthcare advertising has traditionally depended heavily on prescription and claims data for audience construction, measurement and attribution. Those datasets provide valuable longitudinal information but are not designed to function as instantaneous advertising signals.
At the same time, pharmaceutical marketers are expanding across CTV, social, programmatic, point-of-care and digital publisher environments. This increases the need for identity and measurement systems capable of connecting activity across fragmented channels.
Doceree’s approach sits at the intersection of healthcare identity, contextual intelligence, programmatic media and predictive advertising. Its emphasis on clinical-intent signals represents a move toward event-driven audience activation, where media decisions respond to current behavior rather than relying exclusively on historical segments.
The broader AdTech market is moving in the same direction. Platforms increasingly use real-time signals, machine learning and automated decisioning to determine which users, impressions and environments deserve advertising investment. Healthcare adds a specialized layer because the underlying signals involve clinical workflows and professional identities.
For pharmaceutical advertisers, the long-term opportunity is a media stack that connects clinical context to activation and measurement without requiring separate audience strategies for every channel.
Top Insights
- Doceree’s new suite brings clinical-intent signals into CTV, LinkedIn social advertising and programmatic media through one orchestration layer.
- The platform aims to reduce the delay between a physician’s clinical activity and the advertising response by moving beyond claims-based audience construction.
- Doceree says its signals can originate from EHR activity, clinical-content engagement and point-of-care interactions, then resolve to verified HCP identities.
- Programmatic activation applies Clinical Intent Signals at the bid level, connecting healthcare intelligence directly to media-buying decisions.
- Closed-loop measurement adds signal-to-exposure latency to conventional campaign metrics, giving pharmaceutical advertisers another way to evaluate real-time media activation.
Get in touch with our Adtech experts.
